NASDAQ
11.12.25 | 21:59
25,150 US-Dollar
-0,98 % -0,250
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.10. | Arcus Biosciences stock falls after pricing $250 million public offering | 3 | Investing.com | ||
| 31.10. | Arcus Biosciences prices $250M offering | 2 | Seeking Alpha | ||
| 31.10. | Arcus Biosciences prices $250 million public offering at $18.25 per share | 2 | Investing.com | ||
| 30.10. | Hedge Fund and Insider Trading News: Paul Tudor Jones, Berkshire Hathaway, Soros Fund Management, Citadel Investment Group, LMR Partners, Iridium Communications Inc (IRDM), Arcus Biosciences Inc (RCUS), and More | 10 | Insider Monkey | ||
| 30.10. | Arcus Biosciences launches public offering of common stock | 1 | Investing.com | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 29.10. | Analyst Expectations For Arcus Biosciences' Future | 2 | Benzinga.com | ||
| 28.10. | Arcus Biosciences: EPS übertrifft Schätzungen um 0,01 $ - Umsatz besser als erwartet | 2 | Investing.com Deutsch | ||
| 28.10. | Arcus Biosciences GAAP EPS of -$1.27 beats by $0.06, revenue of $26M beats by $5.75M | 1 | Seeking Alpha | ||
| 28.10. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.10. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10. | Arcus Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.10. | Arcus Biosciences stock rises after strong gastric cancer survival data | 1 | Investing.com | ||
| 13.10. | Arcus Biosciences-Aktie steigt nach starken Überlebensdaten bei Magenkrebs | 1 | Investing.com Deutsch | ||
| 13.10. | Arcus Biosciences rises on results from domvanalimab cancer study | 1 | Seeking Alpha | ||
| 13.10. | Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months | 24 | Benzinga.com | ||
| 13.10. | Arcus Biosciences to present promising gastric cancer survival data | 1 | Investing.com | ||
| 07.10. | Truist Securities raises Arcus Biosciences stock price target on casdatifan potential | 1 | Investing.com | ||
| 07.10. | Casdatifan-Potenzial: Truist Securities hebt Kursziel für Arcus Biosciences an | 1 | Investing.com Deutsch | ||
| 07.10. | How Arcus Biosciences Aims To Take On Merck In Cancer Treatment | 9 | Investor's Business Daily | ||
| 06.10. | Why Is Arcus Biosciences Stock Trading Higher On Monday? | 1 | Benzinga.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 31,630 | -1,40 % | Viking Therapeutics-Aktie: Was kommt 2026? | Kurz vor Jahresende nehmen wir die Aktie von Viking Therapeutics noch einmal unter die Lupe, denn das Unternehmen steht vor einem entscheidenden Jahr für seine Adipositas-Pipeline. Zwar sind keine Zulassungsentscheidungen... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,220 | +2,42 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| XOMA ROYALTY | 22,800 | -22,97 % | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc | EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 7,852 | -4,55 % | Telix Pharmaceuticals, Varian Team Up To Develop New Theranostic EBRT Applications | CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX) on Wednesday announced collaboration with Varian, a Siemens Healthineers company, to develop new clinical applications that integrate... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,510 | 0,00 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,035 | -2,38 % | Rocket Pharma cut at J.P. Morgan on risks to Danon disease program | ||
| OUTLOOK THERAPEUTICS | 1,757 | -1,95 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD | Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 5,800 | 0,00 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| ROIVANT SCIENCES | 18,380 | +6,27 % | Roivant Sciences: Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day | Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 6,250 | -1,57 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| ANNOVIS BIO | 3,295 | -8,73 % | Annovis Bio Inc.: Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| REIN THERAPEUTICS | 1,270 | -0,78 % | Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis | FDA lifts clinical hold following review of Company's Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests... ► Artikel lesen | |
| QUINCE THERAPEUTICS | 4,410 | 0,00 % | Quince Therapeutics publishes early-stage data on eDSP drug delivery system | ||
| NEUPHORIA THERAPEUTICS | 3,950 | -6,40 % | ISS recommends shareholders vote for Neuphoria's board nominees | ||
| REPARE THERAPEUTICS | 2,140 | -0,23 % | Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc. | CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement... ► Artikel lesen |
Das Unternehmen ARCUS BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,250 (-0,98 %) liegt der Kurs bei 25,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.